NEI Research News

Scientists have identified a protein in the visual system of mice that appears to be key for stabilizing the body’s circadian rhythms by buffering the brain’s response to light.

In a comparative analysis across animals of the many cell types in the retina, researchers concluded that most cell types have an ancient evolutionary history.

This year, the Food and Drug Administration (FDA) approved Syfovre (pegcetacoplan) and Izervay (avacincaptad pegol), the very first drugs for treating geographic atrophy (GA), also known as late-stage “dry” age-related macular degeneration (AMD).

A longstanding member of the NEI/NIH community, Emily Chew, M.D., has been promoted to the title of NIH Distinguished Investigator for her tireless and prolific work as a care provider and clinical trialist.

A multidisciplinary team led by researchers at the Schepens Eye Research Institute of Mass Eye and Ear has identified a promising new strategy for glaucoma cell replacement therapy.

NEI-funded investigators at Washington University in St. Louis discovered a potential new treatment approach to diabetic retinopathy, one of the most common causes of vision loss in the U.S.

Members of the National Eye Institute's Audacious Goals Initiative (AGI) published an outline of milestones to reach before commencing clinical trials of regenerative therapies for retinal disease.

Research suggests that age-related macular degeneration (AMD) decreases an essential fatty acid, preventing the formation of a class of protective molecules and reducing repair potential.

Researchers found that diabetes, age-related health conditions and other metabolic disorders can lead to a buildup of cholesterol in the retina, which could contribute to diabetic retinopathy.

University of California Irvine (UCI) researchers believe they have discovered a special antibody that may lead to a treatment for an inherited eye disease called retinitis pigmentosa.